KRAS et cancer colorectal : un pas de géant vers la médecine personnalisée

摘要: Summary Colorectal cancer is the third cause of and second most common death from in France. Owing to important advances our understanding molecular biochemical events involved process carcinogenesis tumor growth, therapy, especially colorectal has entered a new era. In this cancer, targeted therapy appeared last past few years with two antibodies epidermal growth factor receptor (EGFR): cetuximab panitumumab. Numerous studies have shown benefit these patients metastatic cancer. However, limited wild-type KRAS gene only. Actually, mutated associated anti-EGFR resistance. Therefore, mutation are mandatory before adding chemotherapy. These findings represent an step forward field personalized medicine which defined as determination optimal treatment for each patient order avoid overtreatment drugs that potentially toxic adverse effects but little benefit. A branch rising, medicine.